Crohns Disease - A Pipeline Analysis Report

Overview of the drug development pipeline for Crohn’s disease

Crohn’s disease is a chronic inflammatory bowel disease that primarily causes inflammation and irritation in the gastrointestinal tract. This disease can affect any part of the gastrointestinal tract but primarily affects the lower part of the intestine called the ileum. Crohn’s disease is consequent in digestive tract and causes abdominal pain, diarrhea, fatigue, and weight loss. It has been reported that in 2015, around 1.3% of the population of the US were diagnosed with IBD (ulcerative colitis and Crohn’s disease).  Technavio’s market research analysts have predicted that with the introduction and administration of anti-inflammatory drugs such as corticosteroids and immunomodulators as one of the effective therapeutic approaches for treatment, the global pharmaceutical market will witness growth in the forthcoming years.   

According to this pipeline analysis report, most of the molecules in the pipeline are under the pre-clinical drug development stage. Our market research analysts have also identified that significant amount of drug molecules are under the phase I/II and phase II drug development stage. The pipeline landscape in the pipeline analysis report also mentions the percentage of drug development molecules that are in phase I, phase III, and discovery stages.

Companies covered

This pipeline analysis report provides a detailed analysis of the companies that are involved in the drug development of therapeutic molecules for the treatment of Crohn’s disease. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the drug development molecules discontinued by companies.

Some of the companies covered in this pipeline analysis report are:

• ALLERGAN
• ALPHA CANCER TECHNOLOGIES
• ATLANTIC HEALTHCARE

Therapeutic assessment of the drug development pipeline for Crohn’s disease by route of administration

• Oral
• Intravenous
• Subcutaneous
• Subcutaneous and intravenous

The oral route of administration (ROA) involves the administration of drug substances through mouth cavity. It has been observed that the majority of total therapeutics for Crohn’s disease are being developed for oral administration, due to the ease of administration and acceptance.

Therapeutic assessment of the drug development pipeline for Crohn’s disease by therapies employed

• Monotherapy
• Combination therapy

According to this pipeline analysis report, the drug development pipeline for Crohn’s disease are primarily employing the monotherapy technique. In this therapeutic strategy, a single drug is administered to treat a particular disorder.  

Technavio also offers customization on reports based on specific client requirement.